Sponsorers syn på framtidens studier
Focused on R&D in three main therapy areas and across key platforms

Main therapy areas

- Oncology
- Cardiovascular and metabolic diseases
- Respiratory

Opportunity-led

- Autoimmunity, neuroscience and infection
Healthcare sector is best placed to benefit from the merging of physical, digital and biological systems, but it is among the least well prepared.  

1. Power to the patient: How mobile technology is transforming healthcare. The Economist Intelligence Unit Report 2015
Innovative medicines are needed more than ever.

- 8 million lives claimed by cancer every year.
- 17 million deaths from cardiovascular disease every year.
- 347 million people worldwide have diabetes.
- 235 million people suffer from asthma.

Source: WHO
For more than 40 years, we have developed cancer drugs. Our vision is to help patients by redefining the cancer treatment paradigm and one day eliminate cancer as cause of death.

Main therapy areas
- Breast
- Ovaries
- Lungs
- Hematologic

Specific orientations
- Tumour drivers and resistance
- DNA damage response (DDR)
- Antibody conjugates
- Immuno-oncology (IO)
Because we know that cardiovascular diseases are a well-known consequence of diabetes and chronic kidney disease, we take an integrated patient-centric approach. We seek to reduce cardiovascular morbidity and mortality, and organ damage by addressing multiple cardiovascular risk factors.
Our goal is to establish a leading position in asthma and COPD treatment, by delivering a range of differentiated inhaled therapies, novel combinations and devices, and biologics.
The future of Clinical Drug Development

Increased participation through reduced burden (both patients and investigators)

Reduce cost and time while quality is non-negotiable

Technology and access will enable and force transformation

Digital 4.0 (digitalization, mobilization & patient power) will be disruptive and lead into a world of integrated/unified solutions